Market research
NVUS Eledon Pharmaceuticals, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 21M
- P/E ratio
- 2.09
- Analyst target
- 35
- Dividend yield
- 0.0%
- Beta
- 2.31
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US67011N2045
- Market cap
- 21M
- P/E ratio
- 2.09
- Analyst target
- 35
- Dividend yield
- 0.0%
- Beta
- 2.31
About
About Eledon Pharmaceuticals, Inc
Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NVUS discussion.
5 years, 4 months ago
Eledon Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 13.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Eledon Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 112.4% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 80.6% to $-561K since the same quarter in the previous year.
Based on the above factors, Eledon Pharmaceuticals, Inc gets an overall score of 2/5.